BNP Paribas Financial Markets
DNTH icon

BNP Paribas Financial Markets’s Dianthus Therapeutics DNTH Stock Holding History

BNP Paribas Financial Markets’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$815K Sell
8,361
-227,387
-96% -$19.9M ﹤0.01% 3458
2026
Q1 		$19.8M Sell
235,748
-240,001
-50% -$13.9M 0.01% 1158
2025
Q4 		$19.6M Buy
475,749
+441,156
+1,275% +$17.1M 0.01% 1197
2025
Q3 		$1.36M Sell
34,593
-14,938
-30% -$382K ﹤0.01% 2908
2025
Q2 		$923K Buy
49,531
+48,173
+3,547% +$904K ﹤0.01% 2960
2025
Q1 		$24.6K Sell
1,358
-1,337
-50% -$29.5K ﹤0.01% 4476
2024
Q4 		$58.8K Buy
+2,695
New +$69.3K ﹤0.01% 4357
2023
Q3 		– Sell
-280
Closed -$3.39K – 3949
2023
Q2 		$3.39K Sell
280
-25
-8% -$284 ﹤0.01% 3695
2023
Q1 		$3.88K Sell
305
-53
-15% -$587 ﹤0.01% 3602
2022
Q4 		$2.27K Buy
358
+34
+10% +$602 ﹤0.01% 3729
2022
Q3 		$7.32K Sell
324
-1,416
-81% -$38.8K ﹤0.01% 4211
2022
Q2 		$33.4K Buy
1,740
+1,449
+498% +$35.8K ﹤0.01% 3641
2022
Q1 		$13.5K Sell
291
-124
-30% -$6.77K ﹤0.01% 3766
2021
Q4 		$29.4K Buy
415
+73
+21% +$7.34K ﹤0.01% 3815
2021
Q3 		$39.8K Buy
342
+278
+434% +$32.4K ﹤0.01% 3566
2021
Q2 		$9.98K Sell
64
-137
-68% -$25.2K ﹤0.01% 3727
2021
Q1 		$38.1K Sell
201
-38
-16% -$6.39K ﹤0.01% 3668
2020
Q4 		$30K Sell
239
-65
-21% -$7.37K ﹤0.01% 3755
2020
Q3 		$33.1K Buy
304
+263
+641% +$31.2K ﹤0.01% 3646
2020
Q2 		$4.93K Sell
41
-332
-89% -$46.8K ﹤0.01% 4011
2020
Q1 		$37.5K Buy
373
+231
+163% +$42.8K ﹤0.01% 3684
2019
Q4 		$34.3K Sell
142
-19
-12% -$3.55K ﹤0.01% 3838
2019
Q3 		$26.4K Buy
161
+60
+59% +$11.4K ﹤0.01% 3824
2019
Q2 		$23.9K Sell
101
-87
-46% -$21.5K ﹤0.01% 3835
2019
Q1 		$49.6K Buy
+188
New +$32.4K ﹤0.01% 3495

Other funds holding DNTH

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
OCA
Octagon Capital Advisors New York $1.11B AUM 866.76% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

BNP Paribas Financial Markets's DNTH Position: Q2 2026 in Review

BNP Paribas Financial Markets reduced its Dianthus Therapeutics (DNTH) stake by 96% in Q2 2026, selling an estimated $19.9M and leaving 8,361 shares worth $815K. The position accounts for ﹤0.01% of the portfolio, ranked #3458.

BNP Paribas Financial Markets first reported a position in DNTH in Q1 2019 and has held it in 25 quarters since. The position peaked at $19.8M in Q1 2026. 223 funds tracked by Wall St. Rank hold DNTH as of Q2 2026.

  • BNP Paribas Financial Markets held 8,361 shares of Dianthus Therapeutics worth $815K as of Q2 2026.
  • BNP Paribas Financial Markets sold 227,387 Dianthus Therapeutics shares in Q2 2026, an estimated $19.9M.
  • Dianthus Therapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3458 holding.
  • BNP Paribas Financial Markets first reported a position in Dianthus Therapeutics in Q1 2019 and has held it in 25 quarters since.
  • BNP Paribas Financial Markets's Dianthus Therapeutics position peaked at $19.8M in Q1 2026.
  • 223 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q2 2026.

Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.